Mankind Pharma Ltd
Mankind Pharma Q2 FY27 results statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and projects.
Based on Mankind Pharma Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statementreports, not management guidance.
The short version
The provided document, dated October 15, 2026, is a press release focused on Mankind Pharma's acquisition of a majority stake in Armed Cell Therapeutics and does not present any revenue, sales, or volume figures for any quarter. EBITDA for the quarter: ₹264 crores, up 16% year-on-year - Operating Margin: 15.1% for the quarter, up 110 bps year-on-year - Profit After Tax (PAT): ₹131 crores, up 13% year-on-year - Explicit
From Mankind Pharma Ltd's Q2 FY27 earnings-call transcript · updated 15 Oct 2026.
Revenue & Sales Performance
2 more points from Mankind Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Mankind Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Mankind Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Mankind Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Mankind Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Mankind Pharma Ltd's management said in earlier quarters
Arthneeti Pro · Annual
Mankind Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Mankind Pharma Ltd Q2 FY27 results?
The provided document, dated October 15, 2026, is a press release focused on Mankind Pharma's acquisition of a majority stake in Armed Cell Therapeutics and does not present any revenue, sales, or volume figures for any quarter. EBITDA for the quarter: ₹264 crores, up 16% year-on-year - Operating Margin: 15.1% for the quarter, up 110 bps year-on-year - Profit After Tax (PAT): ₹131 crores, up 13% year-on-year - Explicit
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 45.5 with a market cap of ₹96,966 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
The results statement does not describe any capex, capacity expansion, new plant, or project details, amounts, status, or timelines.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.